MedPath

Boehringer Ingelheim USA Corporation

🇺🇸United States
Ownership
-
Employees
-
Market Cap
-
Website
Clinical Trials
Related News

Observational Study in Patients With Functional Benign Prostatic Hyperplasia Symptoms Who Switched From Phytotherapy to ALNA® (Tamsulosin)

Completed
Conditions
Prostatic Hyperplasia
Interventions
Drug: Tamsulosin
First Posted Date
2014-09-19
Last Posted Date
2014-09-19
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
4150
Registration Number
NCT02244320

Study of FLOMAX® Versus Placebo in Female Patients With Lower Urinary Tract Symptoms (LUTS) With a Significant Component of Voiding Symptoms

Phase 2
Completed
Conditions
Lower Urinary Tract Symptoms
Interventions
Drug: Placebo
Drug: tamsulosin hydrochloride
First Posted Date
2014-09-19
Last Posted Date
2014-09-19
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
74
Registration Number
NCT02244281

Observational Study of Tamsulosin in Patients With Benign Prostatic Hyperplasia

Completed
Conditions
Prostatic Hyperplasia
Interventions
Drug: Tamsulosin
First Posted Date
2014-09-19
Last Posted Date
2014-09-19
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
1060
Registration Number
NCT02245555

Prescription Event Monitoring in Patients With Benign Prostatic Hyperplasia (BPH)

Completed
Conditions
Prostatic Hyperplasia
Interventions
Drug: Secotex®
First Posted Date
2014-09-19
Last Posted Date
2014-09-19
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
811
Registration Number
NCT02244346

Effect of Tipranavir and Ritonavir on the Pharmacokinetic Characteristics of Norethindrone-Ethinyl Estradiol in Healthy Female Adult Volunteers

Phase 1
Terminated
Conditions
Healthy
Interventions
Drug: Tipranavir high dose
Drug: Tipranavir low dose
Drug: Ritonavir low dose
Drug: Ritonavir high dose
Drug: Norethindrone-Ethinyl Estradiol
First Posted Date
2014-09-19
Last Posted Date
2014-09-19
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
52
Registration Number
NCT02245438

Pharmacokinetics of Atorvastatin With Tipranavir/Ritonavir and the Effect of Antacid on the Pharmacokinetics of Single-Dose Tipranavir/Ritonavir in Healthy Volunteers

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: Tipranavir
Drug: Ritonavir
Drug: Atorvastatin
Drug: Maalox
First Posted Date
2014-09-19
Last Posted Date
2014-09-19
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
23
Registration Number
NCT02245269

FLOMAX® Versus HYTRIN® in Patients With the Signs and Symptoms of Benign Prostatic Hyperplasia

Phase 4
Completed
Conditions
Prostatic Hyperplasia
Interventions
Drug: Ascending doses of HYTRIN® capsules
Drug: FLOMAX® capsules
First Posted Date
2014-09-19
Last Posted Date
2014-09-19
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
1993
Registration Number
NCT02244255

Study to Characterise the Effect of Tamsulosin on Lower Urinary Tract Symptoms (LUTS) and Detrusor Motor Activity in Patients Affected by Benign Prostatic Hyperplasia (BPH) and Storage Urinary Symptoms

Phase 4
Completed
Conditions
Prostatic Hyperplasia
Interventions
Drug: Matching placebo capsule
Drug: Tamsulosin HCl controlled release capsules
First Posted Date
2014-09-19
Last Posted Date
2014-09-19
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
153
Registration Number
NCT02245490

The Impact of Alna® Ocas® on Nocturia in Patients With Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia (LUTS/BPH)

Completed
Conditions
Prostatic Hyperplasia
Interventions
Drug: ALNA®OCAS®
First Posted Date
2014-09-19
Last Posted Date
2014-09-19
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
5775
Registration Number
NCT02245542

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BI 60732 in Healthy Male Volunteers

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: BI 60732
Drug: Placebo
First Posted Date
2014-09-19
Last Posted Date
2014-09-19
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
56
Registration Number
NCT02244203
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy